Filter Your Search

  • ?
    Participants who either do not have cancer but are at high risk for developing the disease or have had cancer and are at high risk for developing a new cancer.
  • ?
    These trials look at ways to improve the quality of life of cancer patients, especially those who have side effects from cancer and its treatment. They find new ways to help people cope with pain, nutrition problems, infection, nausea and vomiting, sleep disorders, depression and other health problems.
  • open for enrollment

    A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

    Protocol: OSU-12169

    Eligibility:

    Inclusion Criteria:

    Advanced malignancies (except leukemias), histologically proven at diagnosis;

    Histologically confirmed advanced malignancies that are known to be sensitive to

    PF-03241066 inhibition, e.g. ALK, c-MET and ROS

    Solid tumors must have measurable disease (Recommended Phase 2 Dose Cohort patients

    with non-measurable disease may enter on a case-by-case basis); not required for DDI

    sub-studies.

    Adequate blood cell counts, kidney function, liver function and Eastern Cooperative

    Oncology Group (ECOG) score of 0 or 1 (for the Recommended Phase 2 Cohort, a ECOG

    score of 2 may be allowed on a case-by-case basis)

    Exclusion Criteria:

    Major surgery, radiation therapy or anti-cancer therapy within 2 to 4 weeks of

    starting study treatment, depending on the patient cohort

    Prior stem cell transplant except of patients with neuroblastoma, lymphoma or myeloma

    Active or unstable cardiac disease or heart attack within 3 months of starting study

    treatment

    Principal Investigator: Gregory A Otterson, MD

    Learn More
  • open for enrollment

    Ph I Dose Escalation & Cohort Expansion Study of TSR-042 in Pts w/ Advanced Solid Tumors

    Protocol: OSU-16293

    Principal Investigator: David M O'Malley, MD

    Learn More
  • open for enrollment

    Ph 1, BXQ-350 as a Single Agent by IV w/ Advanced Solid Tumors and Recurrent High-Grade Gliomas

    Protocol: OSU-16182

    Principal Investigator: Vinay K Puduvalli, MD

    Learn More
  • open for enrollment

    Ph 3 Nivolumab, or Nivolumab + Ipilimumab,vs platinum w/ Chemo-Naïve Stage IV/NSCLC.

    Protocol: OSU-15127

    Principal Investigator: Gregory A Otterson, MD

    Learn More
  • open for enrollment

    Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC

    Protocol: OSU-16074

    Eligibility:

    Inclusion Criteria:

    Inclusion Criteria:

    1. Be ≥ 18 years of age on day of signing informed consent.

    2. Have a life expectancy of at least 3 months.

    3. Have a histologically or cytologically confirmed diagnosis of stage IV NSCLC.

    4. Have a performance status of 0 or 1 on the ECOG.

    5. Have a measurable disease based on RECIST 1.1.

    6. Have provided tissue from an archival tissue sample or newly obtained core or

    excisional biopsy of tumor lesion.

    7. In patients with non-squamous non-small cell lung cancer, investigators must be able

    to produce source documentation of the EGFR mutation status or ALK translocation

    status.

    8. Demonstrate adequate organ function.

    9. Female patient of childbearing potential should have a negative urine or serum

    pregnancy test within 72 hours.

    10. Female parents of childbearing potential must be willing to use 2 methods of birth

    control or be surgically sterile.

    11. Male patients must agree to use an adequate method of contraception.

    Exclusion Criteria:

    1. Has received prior treatment with chemotherapy or biologic therapy for stage IV

    NSCLC.

    2. Is currently participating in or has participated in a study of an investigational

    agent or using an investigational device.

    3. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any

    other form of immunosuppressive therapy.

    4. Has had a prior mAb within 4 weeks prior to study Day 1 or who has not recovered from

    adverse events due to agents administered more than 4 weeks earlier.

    5. Has had prior chemotherapy or radiation.

    6. Has a known additional malignancy that is progressing or requires active treatment.

    7. Has known active CNS metastases and/or carcinomatous meningitis.

    8. Has an active autoimmune disease requiring systemic treatment within the past 3

    months or a documented history of clinically severe autoimmune disease, or a syndrome

    that requires systemic steroids or immunosuppressive agents.

    9. Has evidence of interstitial lung disease or active, non-infectious pneumonitis.

    10. Has an active infection requiring systemic therapy.

    11. Has a history or current evidence of any condition, therapy, or laboratory

    abnormality that might confound the results of the trial.

    12. Has known psychiatric or substance abuse disorders.

    13. Is pregnant or breastfeeding, or expecting to conceive or father children within the

    projected duration of the trial.

    14. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or

    CTLA-4 antibody.

    15. Has a known history of HIV.

    16. Has known active Hepatitis B or Hepatitis C.

    17. Has received a live vaccine within 30 days prior to the planned first dose of study

    therapy.

    18. Has a known history of active TB.

    19. Hypersensitivity to pembrolizumab or any of it's excipients.

    Exclusion Criteria:

    Inclusion Criteria:

    1. Be ≥ 18 years of age on day of signing informed consent.

    2. Have a life expectancy of at least 3 months.

    3. Have a histologically or cytologically confirmed diagnosis of stage IV NSCLC.

    4. Have a performance status of 0 or 1 on the ECOG.

    5. Have a measurable disease based on RECIST 1.1.

    6. Have provided tissue from an archival tissue sample or newly obtained core or

    excisional biopsy of tumor lesion.

    7. In patients with non-squamous non-small cell lung cancer, investigators must be able

    to produce source documentation of the EGFR mutation status or ALK translocation

    status.

    8. Demonstrate adequate organ function.

    9. Female patient of childbearing potential should have a negative urine or serum

    pregnancy test within 72 hours.

    10. Female parents of childbearing potential must be willing to use 2 methods of birth

    control or be surgically sterile.

    11. Male patients must agree to use an adequate method of contraception.

    Exclusion Criteria:

    1. Has received prior treatment with chemotherapy or biologic therapy for stage IV

    NSCLC.

    2. Is currently participating in or has participated in a study of an investigational

    agent or using an investigational device.

    3. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any

    other form of immunosuppressive therapy.

    4. Has had a prior mAb within 4 weeks prior to study Day 1 or who has not recovered from

    adverse events due to agents administered more than 4 weeks earlier.

    5. Has had prior chemotherapy or radiation.

    6. Has a known additional malignancy that is progressing or requires active treatment.

    7. Has known active CNS metastases and/or carcinomatous meningitis.

    8. Has an active autoimmune disease requiring systemic treatment within the past 3

    months or a documented history of clinically severe autoimmune disease, or a syndrome

    that requires systemic steroids or immunosuppressive agents.

    9. Has evidence of interstitial lung disease or active, non-infectious pneumonitis.

    10. Has an active infection requiring systemic therapy.

    11. Has a history or current evidence of any condition, therapy, or laboratory

    abnormality that might confound the results of the trial.

    12. Has known psychiatric or substance abuse disorders.

    13. Is pregnant or breastfeeding, or expecting to conceive or father children within the

    projected duration of the trial.

    14. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or

    CTLA-4 antibody.

    15. Has a known history of HIV.

    16. Has known active Hepatitis B or Hepatitis C.

    17. Has received a live vaccine within 30 days prior to the planned first dose of study

    therapy.

    18. Has a known history of active TB.

    19. Hypersensitivity to pembrolizumab or any of it's excipients.

    Principal Investigator: Gregory A Otterson, MD

    Learn More
  • open for enrollment

    A Study of BMS-986156 Given Alone and in Combination With Nivolumab in Subjects With Advanced Solid Tumors

    Protocol: OSU-16195

    Eligibility:

    Inclusion Criteria:

    For Dose Escalation:

    Subjects with any previously treated advanced (metastatic or refractory) solid

    tumor

    For Cohort Expansion:

    Subjects must have a previously treated advanced solid tumor to be eligible

    Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

    Willing and able to provide pre-treatment and on-treatment fresh tumor biopsy

    Women of child-bearing potential and men must use an acceptable method of

    contraception during treatment and for 23 weeks after treatment for women and 31

    weeks for men

    Exclusion Criteria:

    Known central nervous system metastases or central nervous system as the only source

    of disease

    Other concomitant malignancies (with some exceptions per protocol)

    Active, known or suspected autoimmune disease

    Uncontrolled or significant cardiovascular disease

    History of active or chronic hepatitis (e.g. Hep B or C)

    Impaired liver or bone marrow function

    Major surgery less than 1 month before start of the study

    Principal Investigator: David M O'Malley, MD

    Learn More
  • open for enrollment

    Sublobar Resection or Stereotactic Ablative Radiotherapy in Treating Patients with Stage I Non-small Cell Lung Cancer

    Protocol: OSU-15158

    Eligibility:

    Inclusion Criteria:

    Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2

    Radiographic findings consistent with non-small cell lung cancer, including lesions with ground glass opacities with a solid component of 50% or greater; those with ground glass opacities and < 50% solid component will be excluded

    Biopsy confirmed non-small cell lung cancer

    Tumor =< 4 cm maximum diameter, including clinical stage IA and selected IB by positron emission therapy (PET)/computed tomography (CT) scan of the chest and upper abdomen performed within 60 days prior to registration

    All clinically suspicious mediastinal N1, N2, or N3 lymph nodes (> 1 cm short-axis dimension on CT scan and/or positive on PET scan) confirmed negative for involvement with NSCLC by one of the following methods: mediastinoscopy, anterior mediastinotomy, endoscopic ultrasound (EUS)/endobronchial ultrasound (EBUS) guided needle aspiration, CT-guided, video-assisted thoracoscopic or open lymph node biopsy

    Tumor verified by a thoracic surgeon to be in a location that will permit sublobar resection

    Tumor located peripherally within the lung; NOTE: peripheral is defined as not touching any surface within 2 cm of the proximal bronchial tree in all directions; patients with non-peripheral (central) tumors are NOT eligible

    No evidence of distant metastases

    Availability of pulmonary function tests (PFTs – spirometry, diffusing capacity of the lungs for carbon monoxide [DLCO], +/- arterial blood gases) within 90 days prior to registration; patients with tracheotomy, etc, who are physically unable to perform PFTs are potentially still eligible if a study credentialed thoracic surgeon documents that the patient’s health characteristics would otherwise have been acceptable for eligibility as a high risk but nonetheless operable patient (in particular be eligible for sublobar resection)

    Patient at high-risk for surgery by meeting a minimum of one major criteria or two minor criteria as described below:

    Major criteria

    • Forced expiratory volume in 1 second (FEV1) =< 50% predicted
    • DLCO =< 50% predicted

    Minor criteria

    • FEV1 51-60% predicted
    • DLCO 51-60% predicted
    • Pulmonary hypertension (defined as a pulmonary artery systolic pressure greater than 40 mm Hg) as estimated by echocardiography or right heart catheterization
    • Poor left ventricular function (defined as an ejection fraction of 40% or less)
    • Resting or exercise arterial partial pressure of oxygen (pO2) =< 55 mm Hg or peripheral capillary oxygen saturation (SpO2) =< 88%
    • Partial pressure of carbon dioxide (pCO2) > 45 mm Hg
    • Study credentialed thoracic surgeon believes the patient is potentially operable but that a lobectomy or pneumonectomy would be poorly tolerated by the patient for tangible or intangible reasons
    • Modified medical research council (MMRC) dyspnea scale >= 3

    No prior intra-thoracic radiation therapy; NOTE: previous radiotherapy as part of treatment for head and neck, breast, or other non-thoracic cancer is permitted so long as possible radiation fields would not overlap; previous chemotherapy or surgical resection specifically for the lung cancer being treated on this protocol is NOT permitted; no prior lung resection on the ipsilateral side

    Non-pregnant and non-lactating; women of child-bearing potential must have a negative urine or serum pregnancy test within 60 days prior to registration; peri-menopausal women must be amenorrheic >= 12 months prior to registration to be considered not of childbearing potential

    No prior invasive malignancy, unless disease-free for >= 3 years prior to registration (exceptions: non-melanoma skin cancer, in-situ cancers)

    Ability to understand and the willingness to sign a written informed consent

    Principal Investigator: Terence M Williams, MD, PhD

    Learn More
  • open for enrollment

    Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies

    Protocol: OSU-15241

    Eligibility:

    Inclusion Criteria:

    Inclusion Criteria:

    1. Male or female subjects, age 18 years or older on day of signing consent

    2. Part 1: Any advanced solid tumor malignancy; Part 2: Subjects with squamous non-small

    cell lung cancer, cholangiocarcinoma/gastric cancer, urothelial cancer,

    breast/endometrial cancer, multiple myeloma, or MPNs that have a tumor or malignancy

    that has been evaluated and confirmed to harbor genetic alterations in FGF or FGFR

    genes. A subject's fibroblast growth factor (FGF) or fibroblast growth factor

    receptor (FGFR) alteration may be based on local or central laboratory results. Part

    3: Dose finding: subjects with solid tumor malignancies who qualify for combo

    therapy; dose-expansion: FGF/FGFR+ subjects qualified to receive combo therapy

    3. Has progressed after prior therapy and there is no further effective standard

    anticancer therapy available (including subject refuses or is intolerant)

    4. Life expectancy > 12 weeks

    5. Eastern Cooperative Oncology Group (ECOG) performance status:

    Part 1: 0 or 1

    Part 2 and 3: 0, 1, or 2

    Exclusion Criteria:

    1. Treatment with other investigational study drug for any indication for any reason, or

    receipt of anticancer medications within 21 days or 5 half-lives before first dose of

    study drug

    2. Prior receipt of a selective FGFR inhibitor

    3. History of a calcium/phosphate homeostasis disorder

    4. History and/or current evidence of ectopic mineralization/calcification

    5. Current evidence of corneal disorder/keratopathy

    6. Has a history or presence of inadequate liver, renal, hematopoietic and/or cardiac

    function parameters outside protocol-defined range

    7. Prior radiotherapy within 2 weeks of study treatment

    Exclusion Criteria:

    Inclusion Criteria:

    1. Male or female subjects, age 18 years or older on day of signing consent

    2. Part 1: Any advanced solid tumor malignancy; Part 2: Subjects with squamous non-small

    cell lung cancer, cholangiocarcinoma/gastric cancer, urothelial cancer,

    breast/endometrial cancer, multiple myeloma, or MPNs that have a tumor or malignancy

    that has been evaluated and confirmed to harbor genetic alterations in FGF or FGFR

    genes. A subject's fibroblast growth factor (FGF) or fibroblast growth factor

    receptor (FGFR) alteration may be based on local or central laboratory results. Part

    3: Dose finding: subjects with solid tumor malignancies who qualify for combo

    therapy; dose-expansion: FGF/FGFR+ subjects qualified to receive combo therapy

    3. Has progressed after prior therapy and there is no further effective standard

    anticancer therapy available (including subject refuses or is intolerant)

    4. Life expectancy > 12 weeks

    5. Eastern Cooperative Oncology Group (ECOG) performance status:

    Part 1: 0 or 1

    Part 2 and 3: 0, 1, or 2

    Exclusion Criteria:

    1. Treatment with other investigational study drug for any indication for any reason, or

    receipt of anticancer medications within 21 days or 5 half-lives before first dose of

    study drug

    2. Prior receipt of a selective FGFR inhibitor

    3. History of a calcium/phosphate homeostasis disorder

    4. History and/or current evidence of ectopic mineralization/calcification

    5. Current evidence of corneal disorder/keratopathy

    6. Has a history or presence of inadequate liver, renal, hematopoietic and/or cardiac

    function parameters outside protocol-defined range

    7. Prior radiotherapy within 2 weeks of study treatment

    Principal Investigator: Sameek Roychowdhury, MD, PhD

    Learn More